Oxytocin during myomectomy: a randomized study

What Was Tested

This randomized controlled trial paper looks at Oxytocin.

To evaluate the influence of oxytocin on peroperative blood loss during myomectomy.

Who Took Part

The study group was 2002, patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

From October 1998 to May 2002, 94 patients requiring surgical myomectomy by laparotomy or by the vaginal approach were enrolled in a randomized double blind study.

Patients were randomized to two groups.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Oxytocin could be set against what happens without it.

In the first group (47 patients) oxytocin was administered during myomectomy and in the second group (47 patients) a placebo was used.

The main outcome measures were peroperative blood loss and rates of blood transfusion and autotransfusion.

What Was Measured

PubMed files the paper under topics including Blood Loss, Surgical, Blood Transfusion, Hemoglobins, Leiomyoma, Oxytocin and Uterine Neoplasms.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin in 2002, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.

More context: the Oxytocin compound page, all human trials.